Sumanta (Monty) Kumar Pal, MD, the youngest professor I have ever known and a GU medical oncologist at City of Hope, breaks down diagnosing and administering definitive therapy for localized muscle-invasive bladder cancer, postoperative management options for patients with residual disease, optimizing treatment decisions for metastatic disease, and more.
Monty is an amazing researcher, mentor, and a human being. I interviewed him at the 2019-ASCO, but it took a while to air his episode but it was a great way to start 2020 as the first podcast episode of that year.
This podcast is produced by the Journal of Clinical Pathways.
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
